



To

Date: 14th February, 2023

**The Corporate Relations Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.**

Dear Sir(s),

**Sub: Submission of Un-audited Financial Results for the Quarter ended 31st December, 2022
Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH

The Board at its meeting held today, i.e., Tuesday, 14th February, 2023, transacted inter-alia, the following businesses:

1. Financial Results:
The Board approved the Un-audited Financial Results for the third quarter ended 31st December, 2022. In this regard, please find the enclosed:
 - Un-audited Financial Results of the Company for the quarter ended 31st December, 2022
 - Limited Review Report in respect of the Un-audited Financial Results of the Company for the quarter ended 31st December, 2022
2. Other Corporate matters

The meeting of Board of Directors of the Company commenced at 03:00 P.M and concluded at 04.40 P.M.

The above information is also being made available at website of the Company <http://oxygentapharma.com>

This is for your information and records.

Thanking you

**For OXYGENTA PHARMACEUTICAL LIMITED
(Formerly known as S.S. ORGANICS LIMITED)**

SAI SUDHAKAR
VANKINENI
Digitally signed by SAI
SUDHAKAR VANKINENI
Date: 2023.02.14 16:58:03
+05'30'

VANKINENI SAI SUDHAKAR
Managing Director
DIN: 00733001

OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)
(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.
Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: 202, 2nd Floor, Dwaraka Avenue Appartment, Dwarakapuri Colony, Saibaba Temple Road, Punjagutta, Hyderabad - 500 082. Telangana State

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND 9 MONTHS ENDED 31ST DECEMBER 2022

(Rupees in Lakhs except for EPS)

S. No	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Net Sales/Income from Operations (net of excise duty)	785.20	605.65	1,593.07	2,280.16	5,344.92	6,052.48
	(b) Other Operating Income	1.68	-	0.03	1.68	0.13	0.45
	Total income from operations (net)	786.88	605.65	1,593.10	2,281.85	5,345.05	6,052.94
2	Expenses						
	(a) Cost of materials consumed	812.30	504.86	980.77	2,077.84	3,799.33	4,267.42
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(195.78)	(112.73)	234.27	(385.72)	397.19	454.71
	(d) Direct Manufacturing Expenses	331.58	292.92	238.95	867.96	709.57	545.07
	(e) Employee benefit expense	27.13	28.70	6.77	70.28	25.12	459.99
	(e) Finance Costs	19.80	9.98	21.97	54.69	76.06	92.49
	(f) Depreciation and amortisation expense	40.00	40.00	40.30	120.00	120.90	159.13
	(g) Other expenses	42.59	41.80	48.27	136.81	122.70	177.70
	Total expenses	1,077.62	805.53	1,571.30	2,941.86	5,250.87	6,156.51
3	Profit from operations before other income and exceptional items (1-2)	(290.74)	(199.88)	21.80	(660.02)	94.18	(103.58)
4	Other income						
5	Profit from ordinary activities before exceptional items	(290.74)	(199.88)	21.80	(660.02)	94.18	(103.58)
6	Exceptional (expenses)/income	(34.31)	(33.70)	-	(68.00)	(63.79)	54.64
7	Profit / (Loss) from ordinary activities before tax (7+ 8)	(325.04)	(233.58)	21.80	(728.02)	30.39	(48.95)
8	Tax (expense)/credit						
9	Net Profit / (Loss) from ordinary activities after tax	(325.04)	(233.58)	21.80	(728.02)	30.39	(61.06)
10	Extraordinary items (net of tax expense)						
11	Net Profit / (Loss) for the period (11+ 12)	(325.04)	(233.58)	21.80	(728.02)	30.39	(61.06)
12	Other Comprehensive Income						
13	Total Comprehensive Income	(325.04)	(233.58)	21.80	(728.02)	30.39	(61.06)
14	Share of Profit/(loss) of associates						
15	Minority interest						
16	Paid-up equity share capital (face value Rs. 10/-)	1,420.13	1,420.13	1,420.13	1,420.13	1,420.13	1,420.13
17.i	Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):						
	(a) Basic	(2.29)	(1.64)	0.15	(5.13)	0.21	(0.48)
	(b) Diluted	(2.29)	(1.64)	0.15	(5.13)	0.21	(0.48)
17.ii	Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):						
	(a) Basic	(2.29)	(1.64)	0.15	(5.13)	0.21	(0.48)
	(b) Diluted	(2.29)	(1.64)	0.15	(5.13)	0.21	(0.48)

Notes

- The Unaudited Financial Results of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with the relevant rules thereunder and in terms of regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14-02-2023
- The Company operates in a single segment and the results pertain to a single segment.
- No adjustment is made for Deferred Tax as per Ind AS 12 -Income Taxes, as the same will be provided at the year end.
- The Statutory auditors of the Company have carried out a limited review of the above unaudited standalone financial results for the quarter ended 31 December 2022 and have issued an unqualified Review Report.
- Figures of the previous period have been regrouped and reclassified to confirm to the classification of the current period, wherever necessary.

For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED
(Formerly Known as S. S. ORGANICS LIMITED)

Date: 14-02-2023
Place: Hyderabad

V Sai Sudhakar

SAI SUDHAKAR VANKINENI

Managing Director

DIN :00733001





Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To the Board of Directors


OXYGENTA PHARMACEUTICAL LIMITED

(Formerly known as S. S. ORGANICS LIMITED)

We have reviewed the accompanying Statement of Unaudited Financial Results of **OXYGENTA PHARMACEUTICAL LIMITED**. ("the Company") for the quarter and nine months ended December 31st, 2022 being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. ("the Listing Regulations")

This statement is the responsibility of the company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, (Ind AS 34)' prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries of company personnel for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind - AS) specified under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **Gowri Shankar & Associates**

Chartered Accountants

Firm Registration No. 015625S



Gowri Shankar Seshapu

Partner

M No. 234732

UDIN: 23234732BGQEQN9115



Place: Hyderabad

Date: 14/02/2023